Written by the leading names in pediatric oncology and hematology, Nathan and Oskias Hematology and Oncology of Infancy and Childhood offers you the essential tools you need to overcome the unique challenges and complexities of childhood cancers and hematologic disorders. Meticulously updated, this exciting full-color set brings together the pathophysiology of disease with detailed clinical guidance to provide you with the most comprehensive, authoritative, up-to-date information for diagnosing and treating children. Consult this title on your favorite e-reader, conduct rapid searches, and adjust font sizes for optimal readability. Form a definitive diagnosis and create the best treatment plans possible with comprehensive coverage of all pediatric cancers, including less-common tumors, as well as all hematologic disorders, including newly recognized ones. Develop a thorough, understanding of the underlying science of diseases through summaries of relevant pathophysiology balanced with clear, practical clinical guidance. Nathan and Oskias is the only comprehensive product on the market that relates pathophysiology in such depth to hematologic and oncologic diseases affecting children. Quickly and effortlessly access the key information you need with the help of a consistent organization from chapter to chapter and from volume to volume. Stay at the forefront of your field thanks to new and revised chapters covering topics such as paroxysmal nocturnal hemoglobinuria, lysosomal storage diseases, childhood genetic predisposition to cancer, and oncology informatics. Learn about the latest breakthroughs in diagnosis and management, making this the most complete guide in pediatric hematology and oncology. Discover the latest in focused molecularly targeted therapies derived from the exponential growth of knowledge about basic biology and genetics underlying the field. Rely on it anytime, anywhere!In predominantly white populations, approximately 56% of Rh-positive individuals are heterozygous. ... and do give the physician some indication of risk , their predictive value is inadequate to guide invasive fetal treatment. use of automated analyzers provides somewhat better prediction of the severity of HDFN than manual methods do, but the two approaches have not been compared rigorously.
|Title||:||Nathan and Oski's Hematology and Oncology of Infancy and Childhood|
|Author||:||Stuart H. Orkin, David G. Nathan, David Ginsburg, A. Thomas Look, David E. Fisher, Samuel Lux IV|
|Publisher||:||Elsevier Health Sciences - 2014-11-14|